Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)-Reference-Cited by-同舟云学术

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Published:2010-09 Issue:9 Volume:21 Page:1804-1809
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Reck M.,von Pawel J.,Zatloukal P.,Ramlau R.,Gorbounova V.,Hirsh V.,Leighl N.,Mezger J.,Archer V.,Moore N.,Manegold C.

Funder

Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/9/1804/338312/mdq020.pdf

Reference17 articles.

1. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975;Smit;J Clin Oncol,2003

2. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes;Le Chevalier;Lung Cancer,2005

3. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer;Ferrara;Nat Rev Drug Discov,2004

4. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders;Presta;Cancer Res,1997

5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

Cited by 563 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary sarcomatoid carcinoma: A rare case report, diagnostic dilemma and review of literature;Medicine;2024-07-05

2. A combined model of serum neutrophil extracellular traps, CD8⁺ T cells, and tumor proportion score provides better prediction of PD‐1 inhibitor efficacy in patients with NSCLC;The FEBS Journal;2024-04-25

3. Combination of Anti-Angiogenic and Systemic Therapy in Advanced Non-Small Cell Lung Cancer: Before and After Progression to Leptomeningeal Metastasis;2024-02-02

4. Co-encapsulation of fisetin and cisplatin into liposomes: Stability considerations and in vivo efficacy on lung cancer animal model;International Journal of Pharmaceutics;2024-02

5. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non‒Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial;Journal of Thoracic Oncology;2023-12